Indole S1P Receptor Modulators for IBD With Lower Immunosuppression

The patent applies parameter changes by developing a novel indole derivative with modified chemical structure parameters compared to traditional IBD treatments. The compound features specific substitution patterns (R1-R6 groups) and molecular architecture that alter its biological interaction profile, achieving therapeutic efficacy while minimizing immunosuppressive side effects through optimized molecular parameters

The invention employs composite material principles by creating a complex molecular structure combining indole core with multiple functional groups and substituents. This composite molecular architecture integrates different pharmacophores that work synergistically to provide anti-inflammatory effects with reduced immunosuppression, similar to how composite materials combine different materials to achieve superior properties

The patent applies local quality principle by designing the indole derivative to exhibit selective receptor subtype affinity. The molecular structure is optimized to preferentially bind to S1PR1 over S1PR3, creating localized therapeutic action at the desired receptor site while avoiding harmful interactions with other subtypes. This selectivity is achieved through specific structural features that match S1PR1 binding pocket characteristics

The invention segments the pharmacological action by separating the desired S1PR1-mediated therapeutic effects from the harmful S1PR3-mediated side effects. The indole derivative's molecular structure is divided into functional segments that independently contribute to receptor selectivity, allowing the drug to activate S1PR1 for therapeutic benefit while avoiding S1PR3 activation that causes toxicity and bradycardia